Number of participant |
13,895 |
4694 |
32,432 |
20,756 |
7121 |
26,898 |
Women, % |
65 |
53 |
54 |
53 |
57 |
54 |
Age at ADRD follow‐up start, mean years ± SD |
71.7 ± 5.1 |
69.9 ± 4.2 |
71.0 ± 4.8 |
69.8 ± 4.2 |
69.2 ± 3.9 |
70.4 ± 4.7 |
Education, % |
|
|
|
|
|
|
≤8th grade |
8 |
15 |
3 |
38 |
4 |
3 |
High school |
33 |
25 |
34 |
30 |
49 |
22 |
Vocational school/some college |
35 |
24 |
30 |
21 |
29 |
31 |
Graduated college |
12 |
25 |
19 |
5 |
10 |
20 |
Graduate/professional school |
12 |
11 |
14 |
6 |
8 |
25 |
Cardiometabolic conditions, % |
|
|
|
|
|
|
Heart disease |
12 |
7 |
6 |
9 |
8 |
7 |
Stroke |
4 |
2 |
2 |
2 |
2 |
2 |
Diabetes |
14 |
11 |
10 |
14 |
13 |
5 |
Hypertension |
54 |
42 |
39 |
34 |
44 |
28 |
Medicare usage, % |
|
|
|
|
|
|
In‐patient claims: ≥1 per year |
7 |
3 |
2 |
5 |
4 |
3 |
Out‐patient claims: ≥1 per year |
55 |
47 |
60 |
51 |
57 |
61 |
APOE genotype availability, n (%) |
3735 (27%) |
NA |
4689 (14%) |
2721 (13%) |
2390 (34%) |
2499 (9%) |
Number of ε4 allele, % of individuals with genotype data |
|
|
|
|
|
|
0 (ε3/ε3, ε3/ε2 or ε2/ε2) |
63 |
– |
80 |
77 |
65 |
78 |
1 (ε3/ε4 or ε2/ε4) |
33 |
– |
20 |
23 |
32 |
22 |
2 (ε4/ε4) |
4 |
– |
0 |
0 |
3 |
0 |